MoonLake Immunotherapeutics MLTX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $298.49M-10.8% | $334.52M-4.6% | $350.7M+14.3% | $306.7M+12.9% | $271.6M+50.5% | ||
| $59.43M0.0% | $59.45M+99.9% | $29.74M-74.9% | $118.4M-43.2% | $208.56M-22.1% | ||
| $396.64M-5.9% | $421.69M+2.5% | $411.22M-9.7% | $455.48M-10.0% | $506.26M+6.7% | ||
| $532K-7.8% | $577K-7.2% | $622K-6.7% | $667K-6.2% | $711K-1.5% | ||
| $3.73M+36.3% | $2.74M-12.2% | $3.12M-32.4% | $4.62M-7.7% | $5M+37.2% | ||
| $400.37M-5.7% | $424.43M+2.4% | $414.34M-9.9% | $460.1M-10.0% | $511.26M+7.0% | ||
| $46.11M+1.4% | $45.48M-6.0% | $48.37M+76.8% | $27.36M+14.1% | $23.98M+6.8% | ||
| $99.02M+33.6% | $74.1M+0.5% | $73.74M— | —— | —— | ||
| $100.24M+34.6% | $74.47M-0.4% | $74.78M0.0% | $74.79M+0.1% | $74.7M+3,493% | ||
| $146.35M+22.0% | $119.95M-2.6% | $123.14M+20.5% | $102.15M+3.5% | $98.68M+302% | ||
| -$532.62M-15.1% | -$462.91M-15.6% | -$400.49M-21.1% | -$330.76M-20.0% | -$275.54M-17.0% | ||
| $254.02M-16.6% | $304.48M+5.4% | $288.91M-18.3% | $353.73M-13.2% | $407.52M-8.8% | ||
| $400.37M-5.7% | $424.43M+2.4% | $414.34M-9.9% | $460.1M-10.0% | $511.26M+7.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are MoonLake Immunotherapeutics's total assets?
- MoonLake Immunotherapeutics (MLTX) holds $400.4M in total assets, down 21.7% year over year.
- How much debt does MoonLake Immunotherapeutics have?
- MoonLake Immunotherapeutics carries $100.8M in total debt against $254.0M of shareholders' equity, a debt-to-equity ratio of 0.40.
- How much cash does MoonLake Immunotherapeutics have?
- MoonLake Immunotherapeutics holds $298.5M in cash and equivalents.
- Can MoonLake Immunotherapeutics cover its short-term obligations?
- Its current ratio is 8.60 — current assets exceed current liabilities.
- Where does MoonLake Immunotherapeutics's balance sheet data come from?
- Every line is extracted from MoonLake Immunotherapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.